A Multicentre, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of a Perennial Sublingual Specific Immunotherapy With a Liquid Formulation of an Extract of a Six Grass Pollen-Mixture in Patients With Clinically Relevant Grass Pollen Sensitivity.

Trial Profile

A Multicentre, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of a Perennial Sublingual Specific Immunotherapy With a Liquid Formulation of an Extract of a Six Grass Pollen-Mixture in Patients With Clinically Relevant Grass Pollen Sensitivity.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2014

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Allergic rhinitis; Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Allergopharma
  • Most Recent Events

    • 01 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Apr 2011 Planned End Date changed from 1 Dec 2009 to 1 Sep 2012, according to ClinicalTrials.gov.
    • 17 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top